ELECTRONIC CELL FUSION TECHNIQUE FOR HYBRIDOMAS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$237,436.00
Award Year:
1985
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Award Id:
491
Agency Tracking Number:
491
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
44 Hunt Street, Watertown, MA, 02172
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Gerald Entine Ph.d.
(617) 926-1167
Business Contact:
() -
Research Institution:
n/a
Abstract
"ELECTRONIC CELL FUSION TECHNIQUE FOR HYBRIDOMAS" SBIR - DIV. OF RES. RESOURCES AND/OR NIAID - IMMUNOLOGY. THE PRODUCTION OF HYBRIDOMAS BY CELL FUSION IS AN INCREASINGLY IMPORTANT ASPECT OF BOTH RESEARCH AND CLINICAL PROTOCOLS. ALMOST ALL FUSIONS ARE DONE WITH TECHNIQUES WHICH HAVE LOW ABSOLUTE FUSION EFFICIENCY (TYPICALLY 1 IN 10(5)), REQUIRE LARGE NUMBERS OF CELLS (TYPICALLY 10(9)) AND ARE PARTIALLY TOXIC TO THE CELLS. WE HAVE RECENTLY CONDUCTED PRELIMINARYRESEARCH ON A NEW APPROACH, THE ELECTRONIC CELL FUSION TECHNIQUE. THIS TECHNIQUE USES A MICROCHAMBER WITH ELECTRODES TO CAUSE THE CELLS TO BE HELD BY PAIRS IN CONTACTTO EACH OTHER. AN ELECTRONIC IMPULSE IS THEN USED TO PUNCTURE THE MEMBRANE AT THE POINT OF CONTACT WHICH IMMEDIATELY INDUCES THE ONSET OF FUSION. THIS METHOD HAS THE POTENTIAL TO OVERCOME ALL OF THE LIMITATIONS MENTIONED ABOVE AND MAKE POSSIBLE THE SUCCESSFUL FUSION OF A WIDE VARIETY OF CELL PARTNERS NOT PREVIOUSLY ADDRESSABLE. THE RESULTING HYBRIDOMAS WILL BE OF USE IN MANY AREAS INCLUDING HLA TYPING, ANTITOXIN PRODUCTION AND BASIC RESEARCH. BIOFUSION, INC. IN COLLABORATION WITH THE MASSACHUSETTS GENERAL HOSPITAL PROPOSES TO DO THE RESEARCH NECESSARY TO DEVELOP A RELIABLE AND PRACTICAL ELECTRONIC CELL FUSION APPARATUS ALONG WITH A PROTOCOL SUITABLE FOR THE GENERAL PROBLEM OF CREATING A WIDE VARIETY OF HYBRIDOMAS. IN ADDITION, AS A SPECIFIC PRACTICAL TARGET, AS WELL AS A VEHICLE FOR PROOF OF CONCEPT, WE PROPOSE TO MAKE SPECIFIC HUMAN ANTIBODIES FOR HLA TYPING. IN PHASE I WE WILL FOCUS ON RESEARCH TO DEMONSTRATE BOTH THE POTENTIAL STRENGTHS AND THE PRESENT LIMITATIONS OF THE ELECTRONIC CELL FUSION TECHNIQUE. IN PHASE II, WE WILL PERFECT THE TECHNIQUE AND STRIVE TO MAKE THE HUMAN HLA ANTIBODIES. THE POTENTIAL MARKET FOR MONOCLONAL ANTIBODIES IS EXTREMELY LARGE. THE ABILITY OF THE ELECTRONIC CELL FUSION TECHNIQUE TO FUSE VERYSMALL NUMBERS OF CELLS WITH HIGH EFFICIENCY SHOULD ALLOW BIOFUSION, INC. TO PRODUCE A UNIQUE LINE OF PRODUCTS, ESPECIALLY IN THE AREAS OF HLA TYPING AND ANTITOXINS. BY TEAMING WITH A LARGE COMPANY FOR PHASE III OF THE PROGRAM, THE RESULTS OF A SUCCESSFUL RESEARCH PROGRAM WILL BE OF BOTHSCIENTIFIC AND COMMERCIAL IMPORTANCE IN THE MEDICAL FIELD.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government